Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Deffered Revenue (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $350.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue rose 5.06% to $350.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $350.1 million, a 5.06% increase, with the full-year FY2025 number at $350.1 million, up 5.06% from a year prior.
  • Non-Current Deffered Revenue was $350.1 million for Q4 2025 at Phathom Pharmaceuticals, roughly flat from $349.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $350.1 million in Q4 2025 to a low of $109.5 million in Q4 2022.
  • A 4-year average of $276.8 million and a median of $321.8 million in 2024 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 173.74% in 2023, then grew 5.06% in 2025.
  • Phathom Pharmaceuticals' Non-Current Deffered Revenue stood at $109.5 million in 2022, then surged by 173.74% to $299.8 million in 2023, then rose by 11.16% to $333.3 million in 2024, then rose by 5.06% to $350.1 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Non-Current Deffered Revenue are $350.1 million (Q4 2025), $349.0 million (Q3 2025), and $347.0 million (Q2 2025).